Africa: Senegalese Help Brazil Fight the Zika Virus

http://allafrica.com/stories/201601261297.html

Senegalese researchers who helped contain the Ebola epidemic in West Africa are training Brazilians on how to tackle the Zika virus. They have brought along a mobile lab which quickly detects the virus.

Senegalese researcher Amadou Alpha Sall brought with him to Brazil a small team and a lab which fits into a bag. He wants to help Brazilians defeat the current epidemic of mosquito-borne Zika
…
The head of the Senegalese team believes that the most efficient way to control the epidemic is to quickly identify and isolate infected patients. Zanotto agrees: “People think controlling a vector means killing the mosquito. But controlling a vector means controlling a person in the viremic stage, because it is the patient who infects the mosquito. Once infected, the patient himself turns into a repository for the virus.”

Zika originated in Africa (note: it was extracted from a monkey). But until 2007, it infected only monkeys and didn’t harm humans. Scientists believe that the virus adapted (note: synthetic virologists tinkered) as it spread throughout the continents, becoming more dangerous for humans.

Speculative potential strains/variants:

• Zika virus (original 1947)
• Zika virus (cases 2007)
• Zika virus (French Polynesia 2013)
• Zika virus (Brazil 2015)

Activistpost: Viruses And The GM Insect “Flying Vaccine” Solution

http://www.activistpost.com/2010/12/viruses-and-gm-insect-flying-vaccine.html
DECEMBER 13, 2010
Brandon Turbeville

“…The basic premise behind the flying mosquito vaccines is that an insect will be genetically modified to produce antibodies to a certain disease in their saliva, which is then transmitted to the individual when the mosquito bites them.
There is a host of problems with this method that range from the moral to the scientific. First, the presence of antibodies does not necessarily mean immunity, and the transfer of them does not in any way provide immunization to the subject being injected with them. The science related to antibodies and immunity is still largely unsettled. Vaccines, themselves, are completely ineffective and have never been proven effective by a study that was not connected to a drug company or a pharmaceutical company.[1] They are, essentially, faith-based medicine…”

Full Article: Viruses And The GM Insect “Flying Vaccine” Solution

The poison of the pampas

Uploaded on Dec 21, 2010
Argentinian TV Programme from April 18, 2010, hosted by journalist Rolando Graña: The poison of the pampas – El veneno de las pampas Englisch Subtitles Das Gift der Pampa Deutsche Untertitel Part 2

Note: Monsanto’s glyphosate was the culprit in Argentinia. So what will it be, flimsy zika virus via mosquitoes, tdap vaccine or environmental pollutants?
Will the Brazilian statists and their corporate partners openly share the evidence?

Other links:
Roundup and birth defects: Is the public being kept in the dark?
New Study Shows Direct Link Between Monsanto’s Glyphosate And Birth Defects
Monsanto’s Darkest Secret: Roundup’s Effect On The Fetus

An alternative viewpoint on “Zika”

THERE IS AN ERROR IN THE VACCINE/SHRUNKEN BABY BRAIN REPORT THAT MUST BE FIXED
http://www.jimstone.is/zika.html

https://jhaines6a.wordpress.com/2016/01/25/comment-from-r-on-the-zika-virus-and-the-rollout-of-the-new-vaccines-j/

They are now fronting brain damage caused by a newly formulated Tdap vaccine as a “Zika virus outbreak”. Problem: The Zika virus, which has been known about for 70 years, has never done anything to babies while the mother was pregnant. Zika results in a mild cold and is all over the world now doing nothing to anyone with a mortality rate of ZERO.
QUESTION: why did it suddenly blow the brains out of thousands of babies in ONE LOCATION – Brazil in the past two months alone when ZERO reported cases of this outcome have ever been recorded prior?
ANSWER: Because a new Tdap vaccine, which was spawned to destroy babies before they were born rather than after birth (due to the new awareness that autism is caused by intentionally destructive vaccines) was launched in Brazil in May of 2015. Gates&Cohorts now need a scapegoat to pin the damage on, and “ZIKA” sounded spooky enough.

Brazilian Shrunken Head Babies: Zika or Tdap?

In late 2014, the Ministry of Health of Brazil announced the introduction of the Tdap (Tetanus, diphtheria, and acellular pertussis) vaccine for all pregnant women in that country as part of its routine vaccination program. The move was aimed at trying to contain the resurgence of pertussis in Brazil
…
“Unsurprisingly, the Brazilian government announced on January 15, 2016 it will direct funds to a biomedical research center (Sao Paulo-based Butantan Institute) to help develop a vaccine against Zika. Development of the vaccine is expected to take 3-5 years. Again, no consideration to the irony that you may be developing a vaccine to address a problem that may have been CAUSED by a vaccine, and that that new vaccine may COMPOUND the problem No consideration to the possibility that the answer to the problem may not be to do MORE, but rather to do LESS (simply STOP giving Tdcap to pregnant women).”

Note: We have two things worth noting, GM mosquito trials and the use of a new TDAP vaccine in Brazil. The medical records of the affected babies and their mothers will show directly the causal link between TDAP vaccines and microcephaly. If all the mothers of the affected babies had the new TDAP vaccine, we have a direct causal link and can discount “Zika” virus.
Zika is being used to justify further research by the synthetic biologists  – Oxitec/Brazil – and birth control – do NOT get pregant during the “Zika pandemic”.
updated 27/01/2016

RT: Genetically engineered mosquitoes battle Zika virus in Brazil

https://www.rt.com/news/329504-gm-mosquito-zika-virus-brazil/

The ‘Friendly Aedes aegypti Project’ conducted by the company’s subsidiary Oxitec aims to tackle the virus spread in the city of Piracicaba, based on the success of previous preventative measures introduced across Central and South America.

“As the principal source for the fastest growing vector-borne infection in the world in Dengue Fever, as well as the increasingly challenging Zika virus, controlling the Aedes aegypti population provides the best defense against these serious diseases for which there are no cures,” said Oxitec CEO Hadyn Parry.
…Oxitec is initiating a new mosquito production facility in Piracicaba that will have capacity to protect over 300,000 people,”

…Oxitec’s previous trials on mosquito population began in April 2015 after Brazil’s National Biosafety Committee (CTNBio) gave the green light for the UK company to release the insects into the wild.

“By the end of the calendar year, results had already indicated a reduction in wild mosquito larvae by 82 percent. Oxitec’s efficacy trials across Brazil, Panama and the Cayman Islands all resulted in a greater than 90 percent suppression of the wild Ae. aegypti mosquito population – an unprecedented level of control,” the statement said.

Marketwatch Oxitec aricle

“Intrexon Corporation [http://www.dna.com/] , a leader in synthetic biology, today announced its subsidiary Oxitec and Piracicaba City Hall have expanded the ‘Friendly Aedes aegypti Project’ in Piracicaba, Brazil following strong results for controlling the Ae. aegypti mosquito population, the primary vector for dengue, chikungunya and Zika virus outbreaks around the world
…
Samuel Broder, M.D., SVP and Head of Intrexon’s Health Sector commented, “As a vector that transmits a number of serious diseases, the Aedes aegypti mosquito poses a major threat to public health and the economic welfare of nations. Brazil has been hard hit by dengue and the situation there has been aggravated by the recent introduction of Zika virus infections leading to a startling increase in the number of children being born with microcephaly.” Dr. Broder continued, “Through the responsible engineering of biology, we demonstrate a new paradigm of species-specific vector control resulting in dramatic reductions of dangerous mosquitoes, without persistence or harm to the ecosystem, representing a major scientific, environmental and clinical advance.”

 

Oxitec: How the technology works

How the technology works from Oxitec Limited on Vimeo.
Note: These posts on Oxitec and their GM Mosqitoes are not meant to induce fear or anxiety. My intention is that an awareness will actually diffuse any fear-mongering narrative that aims to profit and support the agenda of the gene splicers!

Wellcome Trust: Oxitec mosquitoes combat Dengue Fever

Oxitec mosquitoes combat Dengue Fever from Oxitec Limited on Vimeo.

Aedes aegypti OX513A

http://www.oxitec.com/health/our-products/aedes-agypti-ox513a/
Product profile
OX513A is a bisex RIDL strain. Males are released to mate with wild females. The progeny of such matings die as late larvae or pupae. Continual releases of sufficient numbers of RIDL males will reduce the target population to below the level needed to transmit disease. The late lethality means that RIDL larvae compete with wild-type larvae for resources,adding to the overall effectiveness of control. Before release, male and female pupae are separated mechanically, exploiting the fact that they are naturally significantly different in size. The strain contains the DsRed marker which is clearly visible in larvae, a useful tool for quality control in production and effective monitoring in the field. OX513A is available in Asian and Latin American genetic backgrounds.

Status
OX513A has regulatory approvals for import and contained testing in Brazil, Cayman Islands, France, India, Malaysia, Singapore, Thailand, USA and Vietnam. Open field trials have taken place in both Grand Cayman and Malaysia, and are currently also underway in Brazil.

Oxitec (GM Mosqitoes) – Our Team

Oxitec Ltd. was founded in 2002 and is based in Oxford, United Kingdom. As of September 8, 2015, Oxitec Ltd. operates as a subsidiary of Intrexon Corporation.

http://www.oxitec.com/who-we-are/our-team/

Hadyn Parry, Chief Executive Officer

Hadyn has an extensive background in the Life Science sector. During his fifteen-year career at Zeneca/Syngenta he held various positions, including General Manager of Zeneca Plant Sciences and European Director and Global Head of R&D for Advanta, one of the world’s largest seed companies. More recently he was CEO of MNL Pharmaceuticals, a company that was focused on pioneering a novel approach in immunology. Hadyn is also Chairman of Help For Heroes, a charity founded in 2007 to support wounded British soldiers.

Simon Warner, Chief Scientific Officer

Simon has eighteen years of global commercial experience in biotechnology R&D in various roles at Syngenta in the United Kingdom and the United States, leading collaborative programs and delivering biotechnology products in crops for feed and fuel. Additionally, whilst at Syngenta he also worked as the R&D lead on technology acquisition on various agreements. Immediately prior to joining Oxitec, he was Senior Director of Research and Development Programs at Sapphire Energy, a start-up making algae based fuel, based in San Diego, California. Simon has a BSc in biochemistry from UCL and PhD in plant molecular biology from the University of Leicester.

Bill Fleming, Chief Financial Officer

Bill joins us from Bayer Healthcare having held senior finance positions in Europe and the USA. He has a law degree from Cambridge University and is a qualified ACMA. Previously, Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics.

Camilla Beech, Regulatory Affairs Manager

Camilla has extensive international experience in the regulation of biotechnology products and crops. She obtained commercial food approval in the UK for the first GM crop in Europe, and obtained registrations for numerous biotechnology crops in Africa, Asia and the Americas. She advised the Humanitarian Board for Golden Rice on regulatory matters (1997 to 2004), and was a member of both US (BIO) and European Inter-industry groups (EUROPABIO) on The Cartagena Biosafety Protocol, Convention on Biological Diversity and Plant made Pharmaceuticals. Her most recent post was International Regulatory Manager for Syngenta Biotechnology Inc., based in San Diego, California.

Glen Slade, Head of Business Development

Glen has worked in agribusiness since 1998 when he joined Zeneca Agrochemicals as Head of Strategy. There he championed the role of biotechnology in integrated crop solutions, leading to the merger that formed Syngenta. He then worked in independent consulting roles addressing high profile marketing and strategy projects for Syngenta, Arysta and other agribusiness firms. In parallel to this work, Glen set up and ran two IT-related companies. He has a degree from Cambridge University and an MBA from Insead.

BBC: GM insect trials urged for UK

http://www.bbc.co.uk/news/health-35113332

Lord Selborne, who chairs the committee, said: “GM insect technologies have the potential not only to save countless lives worldwide, but also to generate significant economic benefits for UK plc, where we are an acknowledged world leader.”
But he said the technology had come to a “screeching halt because the EU regulatory system is woefully inadequate”.
GM insects are created by inserting DNA into their genome.
New gene editing techniques mean this can be done rapidly and cheaply.
…
Small-scale studies in Brazil and the Cayman Islands, using sterile mosquitoes, resulted in cutting the numbers of dengue insects by more than 90%.
The studies were carried out by the world’s only company currently trialling GM insects, Oxitec, based in Abingdon, Oxfordshire.

Note: A timeline of Zika and Oxitec in Brazil should be ineresting. The corporate technocrat, simply asks is it profitable or is there research funding?